HC Wainwright keeps Neutral on Aardvark Therapeutics with $4 price target

what happened

Analysts at HC Wainwright & Co. maintained their Neutral rating on Aardvark Therapeutics shares and kept the price target at $4.00. According to TradingView, citing Benzinga data, the target implies an upside of about 5.8% from the October 16 close of $3.78.

Dow Jones Newswires reports that the same firm had earlier cut its target from $6.00 to $4.00 per share. The valuation is based on a discounted cash flow analysis and reflects a cautious view of the company's prospects because of the clinical hold on ARD-101.

The note also flags risks, including possible negative clinical results for ARD-101 in hyperphagia linked to Prader-Willi syndrome and uncertainty over the timing of regulatory approvals. Analysts say these factors could significantly affect the company's valuation and share performance.

why it matters

For the market, this signals that key clinical and regulatory milestones remain the main driver of Aardvark's value. Single-drug biotech stocks often react strongly to target revisions and trial news, so such updates matter to investors following the company.

tags

instruments